TriMas Co. (NASDAQ:TRS – Get Free Report) announced a quarterly dividend on Thursday, February 20th, RTT News reports. Investors of record on Friday, February 28th will be paid a dividend of 0.04 per share by the industrial products company on Friday, March 7th. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.69%.
TriMas has raised its dividend payment by an average of 58.7% per year over the last three years.
TriMas Trading Down 1.6 %
Shares of TRS opened at $23.22 on Friday. The company has a current ratio of 2.83, a quick ratio of 1.44 and a debt-to-equity ratio of 0.60. TriMas has a 12-month low of $22.24 and a 12-month high of $28.51. The firm has a 50-day moving average price of $24.21 and a 200 day moving average price of $25.18. The firm has a market capitalization of $942.04 million, a P/E ratio of 36.28 and a beta of 0.66.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on TriMas
About TriMas
TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace, and industrial markets worldwide. The company operates through Packaging, Aerospace, and Specialty Products segments. The Packaging segment offers dispensing products, such as foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume sprayers, and nasal and trigger sprayers; polymeric and steel caps and closures comprising food lids, flip-top and beverage closures, child resistance caps, drum and pail closures, and flexible spouts; polymeric jar products; integrated dispensers; bag-in-box products; and consumable vascular delivery and diagnostic test components under the Rieke, Taplast, Affaba & Ferrari, Intertech, Omega, and Rapak brands.
Read More
- Five stocks we like better than TriMas
- Basic Materials Stocks Investing
- These 4 Low P/E Tech Stocks Could be Breakout-Ready Bargains
- Roth IRA Calculator: Calculate Your Potential Returns
- Palantir Stock Skids—How Much Further Can It Fall?
- 3 Healthcare Dividend Stocks to Buy
- Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?
Receive News & Ratings for TriMas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriMas and related companies with MarketBeat.com's FREE daily email newsletter.